Related Experiment Video

Updated: Jan 17, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

607

ELABELA: a polypeptide with therapeutic potential in cardiovascular diseases

Ping Yan1, Cuicui Meng2, Shujun Yang2

  • 1Department of General Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Frontiers in Cardiovascular Medicine
|September 17, 2025
PubMed

Insights

ELABELA (ELA) is a small molecule polypeptide crucial for cardiovascular health. This review explores ELA

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Medical Research

Background:

  • Cardiovascular diseases (CVDs) pose a significant public health challenge.
  • Current diagnostic and treatment strategies for CVDs require enhancement.
  • The small molecule polypeptide ELABELA (ELA) has emerged as a key player in cardiovascular health.

Purpose of the Study:

  • To review the role of ELABELA (ELA) in cardiovascular development and its underlying mechanisms.
  • To assess the diagnostic value and therapeutic potential of ELA in various CVDs.
  • To explore ELA's utility in conditions like preeclampsia, hypertension, and ischemia-reperfusion injury.

Main Methods:

  • Literature review of studies investigating ELABELA's function in cardiovascular contexts.
  • Analysis of ELA's impact on cardiovascular development and disease pathology.
  • Examination of ELA's diagnostic markers and therapeutic applications.

Main Results:

  • ELABELA (ELA) demonstrates significant roles in cardiovascular development.
  • ELA exhibits potential as a diagnostic marker for CVDs.
  • ELA has shown efficacy in reducing oxidative stress, apoptosis, fibrosis, and hypertension, while promoting angiogenesis.

Conclusions:

  • ELABELA (ELA) is a promising target for both diagnosis and treatment of cardiovascular diseases.
  • Further research into ELA-targeted drugs could lead to novel therapeutic strategies.
  • This review outlines approaches for ELA-based diagnosis and treatment development in CVDs.

Keywords:
APJELAcardiovascular diseasediagnostictherapeutic target

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.1K
Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli07:35

Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli

Published on: June 9, 2014

22.4K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223